NCT02568553 2025-11-26Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin LymphomaNational Cancer Institute (NCI)Phase 1 Completed35 enrolled
NCT02879695 2025-08-15Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic LeukemiaNational Cancer Institute (NCI)Phase 1 Active not recruiting28 enrolled 16 charts